https://ir.ymlib.yonsei.ac.kr/handle/22282913/175445 Sat, 18 Apr 2026 21:05:27 GMT 2026-04-18T21:05:27Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/210259 Title: Assessment of the Diagnostic Value of [68Ga]Ga-FAPI-04 and [18F]FDG PET in a PHMG-p-Induced Pulmonary Fibrosis Murine Model Authors: Kim, So Young; Park, Jun Young; Cho, Ye Lim; Kang, Won Jun; 박준영 Abstract: Background/Objectives: Pulmonary fibrosis is a progressive and fatal lung disease with limited diagnostic and therapeutic options. Fibroblast activation protein (FAP) has emerged as a promising molecular imaging target for the non-invasive assessment of fibrotic activity. This study aimed to evaluate the diagnostic feasibility of [Ga-68]Ga-FAP inhibitor (FAPI) and [F-18]fluorodeoxyglucose ([F-18]FDG) positron emission tomography (PET) for imaging pulmonary fibrosis in a mouse model. Methods: A pulmonary fibrosis model was established by intratracheal administration of polyhexamethylene guanidine-phosphate (PHMG-p) to C57BL/6 mice. Fibrosis severity was quantified by the Ashcroft scoring system using hematoxylin and eosin and Masson's trichrome staining and evaluated by computed tomography (CT) imaging at 7, 14, and 21 days after PHMG-p exposure. PET imaging was performed, and ex vivo biodistribution was assessed after injection of [Ga-68]Ga-FAPI-04 and [F-18]FDG. Results: Histological analysis and Ashcroft scoring revealed greater fibrosis severity in the PHMG-p-treated group. Western blot analysis demonstrated upregulation of FAP expression after PHMG-p exposure. CT showed increased mean lung density, while [Ga-68]Ga-FAPI-04 PET revealed significantly elevated pulmonary uptake of [Ga-68]Ga-FAPI-04 in the PHMG-p-treated group compared with the controls. [F-18]FDG PET imaging also showed higher uptake of [F-18]FDG in the PHMG-p-treated group than in the controls. Ex vivo biodistribution confirmed greater [Ga-68]Ga-FAPI-04 accumulation in the lungs of PHMG-p-treated mice. Conclusions: [Ga-68]Ga-FAPI-04 PET serves as a sensitive imaging biomarker for evaluation of fibrotic activity in PHMG-p-induced pulmonary fibrosis and complements [F-18]FDG PET for assessing disease progression and therapeutic response. Mon, 01 Dec 2025 00:00:00 GMT https://ir.ymlib.yonsei.ac.kr/handle/22282913/210259 2025-12-01T00:00:00Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/210285 Title: Fatigue, Self-Care Behavior, and Quality of Life in Patients Undergoing Home-Based Chemotherapy with a Disposable Elastomeric Infusion Pump Authors: Koh-Woon, Choi; Suk-Jung, Han Abstract: Purpose: This study aimed to examine the relationships between fatigue, self-care behavior, and quality of life (QoL) among patients receiving home-based chemotherapy with a disposable elastomeric infusion pump and to identify general and disease-related factors associated with QoL. Methods: Data were collected from 145 patients with various cancer types receiving home-based chemotherapy using a disposable elastomeric infusion pump. Fatigue was measured using the Korean version of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale. Self-care behavior was assessed with a validated self-report tool, and QoL was evaluated using the Functional Assessment of Cancer Therapy-General (FACT-G). Results: Fatigue was negatively correlated with QoL, whereas self-care behavior was positively correlated. Among general characteristics, occupation, meal frequency, meal portion size, and the self-reported Eastern Cooperative Oncology Group Performance Status (ECOG-PS) were significantly associated with QoL. Multiple regression analysis revealed that fatigue, self-care behavior, and self-reported ECOG-PS were significant predictors of overall QoL, with fatigue being the most influential factor. While most QoL domains were associated with fatigue and self-care behavior, the social/family well-being domain showed no significant correlation. Conclusion: Fatigue and self-care behavior are key factors influencing QoL in patients receiving home-based chemotherapy with a disposable elastomeric infusion pump. Targeted interventions, such as individualized fatigue management, nutritional support, and self-care education tailored to the home environment, are essential for improving patient outcomes. This study underscores the need for structured nursing models that support self-management in home-based chemotherapy with a disposable elastomeric infusion pump, particularly during public health crises such as the COVID-19 pandemic. Mon, 01 Dec 2025 00:00:00 GMT https://ir.ymlib.yonsei.ac.kr/handle/22282913/210285 2025-12-01T00:00:00Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/209522 Title: Dietary management of pediatric patients with kidney disease: recommendations by The Korean Society of Pediatric Nephrology and The Korean Society of Clinical Nutrition Authors: Ahn, Yo Han; Kang, Hee Gyung; Song, Jiyoung; Han, Sangmi; Park, Eujin; Suh, Jin-Soon; Kim, Jeong Yeon; Park, Min Ji; Lee, Keum Hwa; Lim, Seon Hee; Shin, Kyeong Hun; Ko, Hyunji; Lee, Hyun Joo; Jeong, Eunyoung; Kim, Jinsu; Park, Sohyun; Choi, Eonju; Seo, Yuri; Oh, Kyooyung; Kim, Jin Kyoung; Lee, Hyun Kyung Abstract: Pediatric kidney disease has a relatively lower prevalence than do other pediatric conditions and has a notably different etiology from kidney diseases observed in adults. Furthermore, the pediatric population is unique in that they experience ongoing growth and development, distinguishing them from adult patients. Consequently, pediatric patients with kidney disease require more specialized and meticulous nutritional management than do adults. To address this need and promote optimal dietary practices for pediatric patients with kidney disease, pediatric nephrologists from the Korean Society of Pediatric Nephrology and nutritionists from the Korean Society of Clinical Nutrition have collaborated to establish nutritional guidelines specifically tailored to Korean dietary patterns. These guidelines offer detailed, nutrient-specific recommendations covering energy, protein, calcium, phosphorus, and potassium consumption while providing practical, culturally relevant guidance intended to support both pediatric patients and their caregivers. Sat, 01 Nov 2025 00:00:00 GMT https://ir.ymlib.yonsei.ac.kr/handle/22282913/209522 2025-11-01T00:00:00Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/209851 Title: Silk protein discoidal microparticles for site-specific delivery of docetaxel in metastatic lung cancer Authors: Cho, Hyeyoun; Park, Sanghyo; Park, Jun Young; Hwang, Yoonho; Kang, Won Jun; Key, Jaehong; 박준영 Abstract: Silk proteins, such as silk sericin (SS) and silk fibroin (SF), have been shown to exhibit excellent biocompatibility, biodegradability, and low immunogenicity as drug delivery carriers. SS possesses antioxidant and anticancer adjuvant properties, whereas SF provides mechanical strength and structural stability, marking them as optimal materials for drug delivery systems. In this study, 3 mu m discoidal silk protein particles (DSPs) based on silk sericin/silk fibroin (SS/SF) composites were developed for the loading of docetaxel (DTX). A comprehensive analysis was conducted to assess the morphological characteristics, particle size, zeta potential, drug loading content, and colloidal stability of the particles. In vitro studies utilizing human-derived non-small cell lung cancer (A549) and mouse-derived squamous cell carcinoma (SCC7) cell lines revealed that DTX-SS/SF-DSPs exhibited superior anticancer activity compared to both free DTX and DTX-SF-DSPs. In vivo biodistribution studies revealed that DTX-SS/SF-DSPs effectively accumulated in the lungs, with minimal accumulation in non-target organs, including the liver and kidneys. Anticancer efficacy evaluations showed a significant reduction in the number of tumor nodules and improvement in survival rates. Furthermore, histopathological analysis confirmed reduced inflammatory responses and the absence of major organ toxicity, demonstrating excellent biocompatibility. In conclusion, SS/SF-DSPs are a promising drug delivery system that can improve the therapeutic efficacy of anticancer drugs with minimal side effects, which can present a new paradigm in lung cancer treatment. Wed, 01 Oct 2025 00:00:00 GMT https://ir.ymlib.yonsei.ac.kr/handle/22282913/209851 2025-10-01T00:00:00Z